Use of Erythromycin in Mustard-Induced Bronchiolitis

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Male

Summary

We looked for the effectiveness of low-dose long-term prescription of erythromycin in mustard-induced bronchiolitis obliterans

• Phase: Phase 4

Details

• Lead Sponsor: Baqiyatallah Medical Sciences University
• Treatments: Erythromycin; Erythromycin Estolate; Erythromycin Ethylsuccinate; Erythromycin stearate

Criteria

Inclusion Criteria:

• Documented chemical exposure

• Clinical, spirometric and radiological findings were compatible with BO on High Resolution Computed Tomography (HRCT)

• Non-responsiveness to high dose bronchodilator therapy

Exclusion Criteria:

• Radiographic evidence of pneumonia, active tuberculosis, lung carcinoma, or an infection that necessitated the use of an antibiotic

• History of cigarette smoking and occupational exposure to toxic agents of hypersensitivity to macrolides

• History of treatment with a systemic antibiotic within 7 days before the start of the study

• Any investigational medicine within 4 weeks of the study

• History of antibiotic injection within 6 weeks before the study

• Concomitant Theophylline or Carbamazepine, unless their serum concentrations were regularly monitored

• Patients who were in the exacerbation phase of their respiratory complications

• Need to use medications interact with macrolides such as Digoxin, Theophylline and Carbamazepine

• Systemic antibiotics

• Systemic Corticosteroids

• Admission to the hospital

• Abnormal kidney or liver function